Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Ambrx
Ambrx is a clinical stage biopharmaceutical company that uses expanded genetic code technology to develop Engineered Precision Biologics.
Sector
Subsector
Keywords
Location
total rounds
total raised
Xenoport
XenoPort is a biopharmaceutical company that develops treatments for neurological disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Apexigen
Apexigen is a biopharmaceutical company developing products to treat life-threatening and difficult to treat diseases.
Sector
Subsector
Location
total rounds
total raised
VistaGen Therapeutics
VistaGen is a biopharmaceutical company focused on developing innovative treatments for CNS diseases and disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds6
Number of Funding Rounds
Money Raised
Their latest funding was raised on 03.04.2024. Their latest round Post-IPO Equity
Co-Investors
Investors1
Number of lead investors
Number of investors
SternAegis
Aegis Ventures is a corporate venture arm of Aegis Capital that invests in technology, telecom, media, and emerging growth sectors.
Sector
Subsector
Location
count Of Investments
count Of Exists
Acquisitions1
Aquarius Biotechnologies acquired by MATINAS BIOPHARMA
acquirer
date
type
Aquarius Biotechnologies
Aquarius Biotechnologies develops a proprietary drug delivery platform to enhance existing medications.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders3
Jerome D. Jabbour
Jerome D. Jabbour is the Chief Executive Officer at Matinas BioPharma.
current job
organization founded
Jerome D. Jabbour
Roelof Rongen
Mr. Rongen is the Chief Executive Officer and a Co-Founder of Matinas BioPharma. He is also the Founder and Chairman of Essential Fatty Acid Therapeutics, a biotech company focused on the development of innovative fatty acid derivatives. Prior to Matinas BioPharma, Mr. Rongen was Executive Vice President North American Operations for EPAX/Trygg Pharma and Vice President of Life Cycle Management and Intellectual Property at Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. While at Reliant, Mr. Rongen held various earlier positions, including head of the Omacor®/Lovaza® launch team, Executive Director of Marketing for Lescol® and Executive Director of Business Development. Before Reliant, Mr. Rongen was Global Product Director for Humira® at BASF Pharmaceuticals, later acquired by Abbott. He was also a consultant at The Wilkerson Group in New York and with Arthur D. Little in Amsterdam. Mr. Rongen earned an MBA from Kellogg GSM at Northwestern University, and a graduate degree in Molecular Sciences from Wageningen Univerisity in the Netherlands.
organization founded
Roelof Rongen
Abdel A. Fawzy
Abdel A. Fawzy is the Co-Founder and Executive VP at Matinas BioPharma.
current job
organization founded
Abdel A. Fawzy
Employee Profiles12
Gary Gaglione
Cfo, vice president of finance, treasurer
Activity
Recent News4
The graph reveals the ratio (%) of positive news articles in a chosen time range